News Release

Research Article Cites Cleanascite™ for Proteome Analysis of Human Bile Associated with Primary Sclerosing Cholangitis Disease

MONMOUTH JUNCTION, NJ, November 22, 2019 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid clearance sample preparation technology for the proteomic analysis of bile fluid. 

Vesterhus, Mette, et al. "Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis." Journal of hepatology 66.6 (2017): 1214-1222.

The investigators aimed to identify novel protein biomarkers of disease severity and prognosis in primary sclerosing cholangitis (PSC), using a bead-based array targeting 63 proteins. The article states for Bile sample preparation, “The samples were thawed and 100 µL of bile was added to 150 µL PBS containing 0.1% Tween 20 and Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis, Missouri, USA), then centrifuged at 4 °C for 10 minutes at 14000 rpm. Cleanascite™ (100 µL, Biotech Support Group, NJ, USA) and Protein G Sepharose (50 µL; Sigma-Aldrich) were used for removal of lipids and immunoglobulins, respectively.” The authors conclude with the identification of novel biliary and serum biomarkers of severity and prognosis in PSC.

“This reference shows the versatility of Cleanascite™ to efficiently remove lipids from bile fluid, with a selectivity profile suitable for proteome analysis using bead-based capture features.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866

mkuruc@biotechsupportgroup.com